Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial

Cardiovascular Division, Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.

OBJECTIVES. The present study was designed to test the efficacy and safety of a sequential combination of recombinant tissue-type plasminogen activator (rt-PA) and pro-urokinase in patients with acute myocardial infarction. BACKGROUND. Efforts continue to identify a thrombolytic regimen that induces rapid, complete and sustained coronary artery patency in acute myocardial infarction. The two endogenous plasminogen activators rt-PA and pro-urokinase have been shown experimentally to induce fibrinolysis by sequential and complementary mechanisms. As a result, certain combinations of these activators have been found to be synergistic in vitro and in vivo. METHODS. In a multicenter observational study with core facilities for angiographic and laboratory analysis, 101 patients with acute myocardial infarction were enrolled and given a low dose bolus of rt-PA (5 to 10 mg) followed by a 90-min infusion of pro-urokinase (40 mg/h). All patients received intravenous heparin and oral aspirin. Coronary angiography was performed in all patients at 90 min. RESULTS. Angiography at 90 min showed the infarct-related artery to be patent (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3 flow) in 77% of patients, and 60% achieved TIMI grade 3 flow. At one center, angiography was repeated at 24 h to detect a possible reocclusion. All 28 patients with a patent infarct-related artery at 90 min had patency at 24 h (82% achieved TIMI grade 3 flow). Treatment was well tolerated, with bleeding complications essentially confined to arterial puncture site hematomas. There was only one in-hospital death. CONCLUSIONS. A sequential combination of low dose rt-PA and reduced-dose pro-urokinase produced a high TIMI 3 patency rate, was well tolerated and was associated with a low reocclusion rate.

This article has been cited by other articles:

				S. C. Lin, A. Mousa, J. Bernheim, R. Dayal, P. Henderson, S. Hollenbeck, K. C. Kent, and P. L. Faries Endoluminal Recanalization in a Patient with Phlegmasia Cerulea Dolens Using a Multimodality Approach: A Case Report Vascular and Endovascular Surgery, May 1, 2005; 39(3): 273 - 279. [Abstract] [PDF]

				V. Gurewich, G. J. del Zoppo, R. T. Higashida, A. J. Furlan, H. A. Rowley, and M. Gent Intra-arterial Pro-urokinase in Ischemic Stroke • Response Stroke, June 1, 1998; 29(6): 1255 - 1256. [Full Text] [PDF]